Skip to main content
SpringerLink
Log in

Apixaban is safest DOAC in terms of non-major bleeding

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ma F, et al. Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis. European Journal of Clinical Pharmacology : 13 Jun 2023. Available from: URL: http://doi.org/10.1007/s00228-023-03520-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apixaban is safest DOAC in terms of non-major bleeding. Reactions Weekly 1962, 10 (2023). https://doi.org/10.1007/s40278-023-41680-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-41680-z

Search

Navigation